Cequa (Cyclosporine Ophthalmic Solution) for Dry Eye: Mechanism and Clinical Use

Cequa (cyclosporine 0.09% ophthalmic solution) is a calcineurin inhibitor approved to increase tear production in dry eye disease (DED). It uses nanomicellar technology (NCELL®) for enhanced corneal penetration—addressing cyclosporine's historical bioavailability challenge.

Mechanism of Action

  1. T-cell inhibition: Cyclosporine binds cyclophilin, inhibiting calcineurin phosphatase, blocking NFAT nuclear translocation, and decreasing IL-2, IFN-γ, and other T-cell cytokines.
  2. Reduces ocular surface inflammation: DED is T-cell mediated (CD4+ Th1/Th17 infiltration). Cyclosporine interrupts this inflammatory cycle.
  3. Restores lacrimal gland function: Reduced inflammation leads to increased aqueous tear production.
  4. Improves tear quality: Increases mucin (MUC5AC) production by goblet cells, improving tear film stability and ocular surface protection.
  5. NCELL® nanomicelles: ~22 nm particles enhance corneal permeation 3-fold vs. emulsion (Restasis®), allowing lower concentration (0.09% vs. 0.05%) with better delivery.

Clinical Efficacy (Phase 3: OTTER-1 and OTTER-2)

  • Primary endpoint (Month 3): ≥10 mm increase in Schirmer score (with anesthesia): Cequa ~15–17% vs. vehicle ~7–8%.
  • Signs: Improvement in corneal fluorescein staining.
  • Symptoms: Reduction in Ocular Surface Disease Index (OSDI) and eye dryness scores.
  • Onset: Some improvement by 1 month; maximal effect by 3–6 months.

Dosing and Administration

  • One drop (0.09%) in each eye twice daily (~12 hours apart).
  • Single-use vials (preservative-free). Use immediately; discard after use.
  • Wait ≥15 minutes before administering other eye drops.
  • Can be used with artificial tears (separate by 15 minutes).

Safety and Tolerability

  • Common (1–5%): Instillation site pain (burning/stinging), conjunctival hyperemia, blepharitis, headache, upper respiratory infection.
  • No systemic immunosuppression: Negligible blood levels.
  • No increased infection risk in clinical trials.
  • Contact lenses: Remove before instillation; reinsert 15 minutes after.

Comparison: Cequa vs. Restasis vs. Xiidra vs. Tyrvaya

CequaRestasisXiidraTyrvaya
ActiveCsA 0.09%CsA 0.05%Lifitegrast 5%Varenicline 0.03 mg
MechanismCalcineurin inhib.Calcineurin inhib.LFA-1 antagonistCholinergic agonist
VehicleNanomicellarEmulsionSolutionNasal spray
DosingBIDBIDBIDBID nasal
Onset1–3 mo3–6 mo2–12 wkDays–weeks
Burning~20%~17%~15%Sneezing ~80%

Clinical Pearls

  • Set expectations: 3–6 months for full effect. Don't stop early.
  • Refrigeration not required (room temperature OK).
  • Cost/access: Check formulary, manufacturer savings card, patient assistance programs.
  • Combine with: preservative-free artificial tears, lid hygiene, omega-3 supplementation, environmental modification.
  • If inadequate at 6 months: reassess diagnosis (MGD, neuropathic, autoimmune), consider add-on or switch.

Cequa offers improved cyclosporine delivery for dry eye disease. Patience and consistency are key—this treats the disease, not just symptoms.

Eye & Vision Disorders - Related Articles